Automate Your Wheel Strategy on MRNA
With Tiblio's Option Bot, you can configure your own wheel strategy including MRNA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MRNA
- Rev/Share 7.8866
- Book/Share 24.2242
- PB 1.0663
- Debt/Equity 0.0788
- CurrentRatio 3.9256
- ROIC -0.3078
- MktCap 10049930123.0
- FreeCF/Share -9.0206
- PFCF -2.8714
- PE -3.4523
- Debt/Assets 0.0617
- DivYield 0
- ROE -0.2746
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | MRNA | Citigroup | -- | Neutral | -- | $40 | March 13, 2025 |
| Downgrade | MRNA | Barclays | Overweight | Equal Weight | $111 | $45 | Feb. 18, 2025 |
| Downgrade | MRNA | Goldman | Buy | Neutral | $99 | $51 | Jan. 29, 2025 |
| Downgrade | MRNA | Argus | Buy | Hold | -- | -- | Dec. 18, 2024 |
| Resumed | MRNA | BofA Securities | -- | Underperform | -- | $41 | Dec. 10, 2024 |
| Initiation | MRNA | Bernstein | -- | Market Perform | -- | $55 | Oct. 17, 2024 |
| Downgrade | MRNA | Jefferies | Buy | Hold | $120 | $65 | Sept. 13, 2024 |
| Downgrade | MRNA | JP Morgan | Neutral | Underweight | $88 | $70 | Sept. 13, 2024 |
| Downgrade | MRNA | Oppenheimer | Outperform | Perform | -- | -- | Sept. 13, 2024 |
| Upgrade | MRNA | HSBC Securities | Reduce | Hold | -- | $82 | Aug. 28, 2024 |
News
3 Of My Favorite Biotech Stocks Under $10
Published: September 29, 2025 by: Seeking Alpha
Sentiment: Positive
Today, I am highlighting three biotech stocks I like in the current market that are trading at under $10.00 a share. The options on these stocks are also lucrative and liquid, making them well-suited for consistent covered call trades. Covered call strategies offer downside protection in the underperforming, high-beta biotech sector, supporting a rinse, wash, and repeat approach.
Read More
Moderna, Inc. (MRNA) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum Transcript
Published: September 25, 2025 by: Seeking Alpha
Sentiment: Neutral
Moderna, Inc. (NASDAQ:MRNA ) Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum September 25, 2025 10:30 AM EDT Company Participants Rose Loughlin - Executive Vice President of Research Conference Call Participants Courtney Breen - Sanford C. Bernstein & Co., LLC.
Read More
Moderna Announces First Made-in-Canada mRNA Vaccines Delivered to Canadian Provinces and Territories
Published: September 19, 2025 by: Accesswire
Sentiment: Neutral
CAMBRIDGE, MA / ACCESS Newswire / September 19, 2025 / Moderna announced today that the first mRNA vaccines fully manufactured in Canada are being shipped to provinces and territories. This milestone advances Canada's domestic vaccine production capacity and strengthens national health security.
Read More
Mizuho's Jared Holz: There's not much value left in vaccine stocks
Published: September 19, 2025 by: CNBC Television
Sentiment: Negative
Jared Holz, Mizuho healthcare senior strategist, joins CNBC's 'Squawk on the Street' to discuss outlooks on pharmaceuticals, what new government vaccine panel recommendations mean for the stocks, and much more.
Read More
MRNA Stock Rises as Updated COVID-19 Jab Shows Strong Immune Response
Published: September 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Moderna jumps after its updated formulation of Spikevax shows an over 8-fold increase in neutralizing antibodies against the LP.8.1 COVID-19 variant in phase IV study.
Read More
MRNA Stock vs. PFE & ALNY
Published: September 15, 2025 by: Forbes
Sentiment: Negative
On Friday, MRNA stock dropped 7% following a report from The Washington Post that stated a group of health officials reportedly used the Vaccine Adverse Event Reporting System to link the deaths of 25 children to COVID-19 vaccines. This drop brings the stock's year-to-date decline to almost 45%.
Read More
COVID-19 Vaccine Stocks Fall on Reports Linking Shots to Child Deaths
Published: September 15, 2025 by: Zacks Investment Research
Sentiment: Negative
MRNA, BNTX, PFE and NVAX stocks fall as health officials reportedly plan to link COVID-19 vaccines to child deaths ahead of a key CDC meeting.
Read More
Moderna shares hit a low after report suggests the FDA plans to tie COVID shots to child deaths
Published: September 15, 2025 by: Fast Company
Sentiment: Negative
Pharma stocks took a fresh hit on Friday following a report in The Washington Post that the U.S. Food and Drug Administration reportedly plans to link COVID-19 vaccines with the deaths of 25 minors.
Read More
COVID vaccine makers' shares fall as Trump officials to link shots to child deaths, report says
Published: September 12, 2025 by: Market Watch
Sentiment: Negative
Shares of companies that make COVID vaccines sank Friday, after a report raised fears that Trump administration health officials will blame the vaccines for some child deaths.
Read More
Pfizer, Moderna shares fall on report that Trump officials will link child deaths to Covid shots
Published: September 12, 2025 by: CNBC
Sentiment: Negative
Shares of Pfizer and Moderna fell on Friday after a report that Trump administration health officials plan to link Covid vaccines to the deaths of 25 children. The report comes as Health and Human Services Secretary Robert F.
Read More
Moderna, Inc. (MRNA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Published: September 08, 2025 by: Seeking Alpha
Sentiment: Neutral
Moderna, Inc. (NASDAQ:MRNA ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 10:00 AM EDT Company Participants Stéphane Bancel - CEO & Director Conference Call Participants Terence Flynn - Morgan Stanley, Research Division Presentation Terence Flynn Equity Analyst All right. Great. Thanks for joining us, everybody.
Read More
FDA Approves Updated COVID-19 Vaccines but With Restrictions
Published: August 28, 2025 by: Zacks Investment Research
Sentiment: Neutral
FDA clears updated COVID-19 vaccines from Pfizer, Moderna and Novavax but limits access to older adults and high-risk groups.
Read More
Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccines Targeting LP.8.1 Variant of SARS-CoV-2
Published: August 27, 2025 by: Accesswire
Sentiment: Neutral
CAMBRIDGE, MA / ACCESS Newswire / August 27, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Applications (sBLA) for the 2025-2026 formulas for Spikevax® and mNEXSPIKE®, targeting the LP.8.1 variant of SARS-CoV-2 to help prevent COVID-19. The updated formula for Spikevax is now approved for individuals 6 months through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19, and all adults 65 years of age and older.
Read More
Moderna's stock takes a hit as RFK Jr. backs out of some mRNA vaccine deals
Published: August 06, 2025 by: Market Watch
Sentiment: Negative
Moderna Inc. shares are selling off Wednesday, after the Trump administration took aim at the science behind the biotechnology company's vaccines and said it would cancel some contracts and stop funding mRNA drug development.
Read More
Moderna Q2 Earnings Review: Downsizing Triggers Selloff, But I'm Long-Term Bullish
Published: August 04, 2025 by: Seeking Alpha
Sentiment: Negative
Moderna, Inc.'s Q2 2025 earnings highlight a steep revenue decline post-pandemic, with just $0.1bn in revenue and a $(0.8bn) net loss. MRNA stock has plummeted over 70% in the past year, reflecting investor concerns about ongoing losses and limited COVID vaccine demand. Despite recent approval of mNEXSPIRE, guidance suggests heavy 2025 losses, with management focused on downsizing and cost control.
Read More
MRNA Beats on Q2 Earnings & Sales, Stock Down on Lowered Sales View
Published: August 01, 2025 by: Zacks Investment Research
Sentiment: Neutral
MRNA tops Q2 estimates with a narrower loss and revenue beat, but the stock slips after trimming 2025 sales guidance.
Read More
Moderna, Inc. (MRNA) Q2 2025 Earnings Call Transcript
Published: August 01, 2025 by: Seeking Alpha
Sentiment: Neutral
Moderna, Inc. (NASDAQ:MRNA ) Q2 2025 Earnings Conference Call August 1, 2025 8:00 AM ET Company Participants James M. Mock - Chief Financial Officer Lavina Talukdar - Senior VP & Head of Investor Relations Stéphane Bancel - CEO & Director Stephen Hoge - President Conference Call Participants Courtney Breen - Sanford C.
Read More
Moderna slashes full-year sales outlook, reduces headcount
Published: August 01, 2025 by: Proactive Investors
Sentiment: Negative
Moderna Inc (NASDAQ:MRNA, ETR:0QF) shares fell almost 9% in early trade as the pharmaceutical giant lowered its full-year guidance and announced a workforce reduction, overshadowing a Q2 earnings beat. The company lowered its 2025 revenue outlook by $300 million to a range of $1.5 billion to $2.2 billion, attributed to shipment timing.
Read More
Moderna Stock Drops as Firm Cuts Revenue Outlook on UK Vaccine Deliveries Delay
Published: August 01, 2025 by: Investopedia
Sentiment: Negative
Shares of Moderna (MRNA) fell sharply Friday after the company lowered the top end of its full-year revenue outlook because of a delay in vaccine deliveries to the UK.
Read More
Moderna (MRNA) Reports Q2 Loss, Beats Revenue Estimates
Published: August 01, 2025 by: Zacks Investment Research
Sentiment: Neutral
Moderna (MRNA) came out with a quarterly loss of $2.13 per share versus the Zacks Consensus Estimate of a loss of $2.99. This compares to a loss of $3.33 per share a year ago.
Read More
Curious about Moderna (MRNA) Q2 Performance? Explore Wall Street Estimates for Key Metrics
Published: July 29, 2025 by: Zacks Investment Research
Sentiment: Neutral
Evaluate the expected performance of Moderna (MRNA) for the quarter ended June 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Read More
Moderna to Report Q2 Earnings: Is a Beat in Store for the Stock?
Published: July 29, 2025 by: Zacks Investment Research
Sentiment: Negative
MRNA's second-quarter results are likely to spotlight a sharp decline in Spikevax sales, RSV uptake and key pipeline milestones.
Read More
Will These 5 Pharma/Biotech Bigwigs Surpass Q2 Earnings Forecasts?
Published: July 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Let's look at five biotech and drug companies, MRK, AZN, BMY, ABBV and MRNA, slated to release their second-quarter 2025 results this week.
Read More
EU regulator backs Moderna's updated COVID vaccine
Published: July 25, 2025 by: Reuters
Sentiment: Positive
The European Union's drug regulator has recommended approval of Moderna's updated formulation of COVID-19 shot Spikevax, the vaccine maker said on Friday.
Read More
Moderna (MRNA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Published: July 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Moderna (MRNA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Published: July 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Read More
MRNA Stock Up on Full FDA Nod for COVID-19 Jab in Pediatric Patients
Published: July 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Moderna stock jumps 4.5% as the FDA grants full approval for its COVID-19 vaccine in high-risk individuals aged six months to 11 years.
Read More
This Former Meme Stock, Down 93%, is a High-Upside Buy Right Now
Published: July 11, 2025 by: 24/7 Wall Street
Sentiment: Positive
Shares of Moderna (NASDAQ:MRNA) have been long forgotten about since its demand for COVID shots fell off a cliff more than three years ago.
Read More
MRNA Stock Jumps on CDC's Revised RSV Vaccine Recommendations
Published: July 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Moderna rises as CDC expands RSV vaccine guidance to include high-risk adults aged 50-59, boosting mResvia's reach.
Read More
Moderna Stock Gains on Encouraging Flu Vaccine Data
Published: July 01, 2025 by: Zacks Investment Research
Sentiment: Positive
MRNA's mRNA-1010 flu vaccine outperforms GSK's shot by 26.6% in a large phase III trial of adults 50 and older.
Read More
About Moderna, Inc. (MRNA)
- IPO Date 2018-12-07
- Website https://www.modernatx.com
- Industry Biotechnology
- CEO Stephane Bancel
- Employees 5800